Long-Term Control of Breast Cancer Brain Metastases Using Abemaciclib and Letrozole Combination Therapy: A Case...

Area of Science:

• Oncology
• Neuro-oncology
• Pharmacology

Background:

• Breast cancer brain metastases are common and carry a poor prognosis.
• Subtype-specific systemic therapy effects on brain metastases remain largely unknown.
• Effective treatment strategies for breast cancer brain metastases are urgently needed.

Observation:

• A middle-aged premenopausal woman with hormone receptor-positive breast cancer developed brain metastases.
• Initial treatment with whole-brain radiation and chemotherapy showed tumor reduction but caused severe peripheral neuropathy.
• Maintenance therapy with abemaciclib, letrozole, and luteinizing hormone-releasing hormone agonists was initiated.

Findings:

• The combination therapy of abemaciclib (a cyclin-dependent kinase 4/6 inhibitor) and letrozole (endocrine therapy) achieved stable disease.
• No new brain lesions were observed during maintenance therapy.
• This regimen demonstrated long-term control of breast cancer brain metastases without significant adverse events.

Implications:

• Cyclin-dependent kinase 4/6 inhibitors combined with endocrine therapy show efficacy in managing breast cancer brain metastases.
• This treatment approach offers a potential alternative for patients with limited options.
• Further research into subtype-specific therapies for brain metastases is warranted.